Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 301

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 301
---
, no shares and 11,370,621 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024, respectively— 110,791 Series C convertible preferred stock, $0.001 par value, no shares and 18,628,970 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024, respectively— 181,328 Total convertible preferred stock— 330,368 Stockholders’ equity (deficit):Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares issued or outstanding as of September 30, 2025 and December 31, 2024— — Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 44,463,527 and 4,798,721 shares issued, 44,463,527 and 4,722,763 shares outstanding as of September 30, 2025 and December 31, 2024, respectively44 5 Additional paid-in capital557,118 17,000 Accumulated other comprehensive income420 368 Accumulated deficit(235,914)(181,086)Total stockholders’ equity (deficit)321,668 (163,713)Total liabilities, convertible preferred stock and stockholders’ equity (deficit)$339,270 $185,752 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-2

Table of Contents

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(in thousands, except share and per share data) 

(Unaudited)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Operating expenses:Research and development$16,044 $24,582 $45,095 $43,035 General and administrative7,761 3,402 20,275 9,388 Total operating expenses23,805 27,984 65,370 52,423 Loss from operations(23